{"id":"apd515","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"APD515 crosses the blood-brain barrier to antagonize NK1 receptors, which are involved in the emetic pathway. By blocking substance P, a key neurotransmitter in nausea and vomiting, the drug provides antiemetic effects. This mechanism is particularly relevant for chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV).","oneSentence":"APD515 is a selective antagonist of the neurokinin-1 (NK1) receptor that reduces nausea and vomiting by blocking substance P signaling in the chemoreceptor trigger zone and vomiting center.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:28:43.373Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chemotherapy-induced nausea and vomiting (CINV)"},{"name":"Postoperative nausea and vomiting (PONV)"}]},"trialDetails":[{"nctId":"NCT01331746","phase":"PHASE2","title":"Proof-of-concept (PoC) Study of APD515","status":"COMPLETED","sponsor":"Acacia Pharma Ltd","startDate":"2011-09","conditions":"Xerostomia in Advanced Cancer Patients","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"APD515","genericName":"APD515","companyName":"Acacia Pharma Ltd","companyId":"acacia-pharma-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"APD515 is a selective antagonist of the neurokinin-1 (NK1) receptor that reduces nausea and vomiting by blocking substance P signaling in the chemoreceptor trigger zone and vomiting center. Used for Chemotherapy-induced nausea and vomiting (CINV), Postoperative nausea and vomiting (PONV).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}